MARKET

ATAI

ATAI

Atai Beckley Inc
NASDAQ
7.18
+0.01
+0.14%
After Hours: 7.14 -0.04 -0.56% 19:53 07/24 EDT
OPEN
7.17
PREV CLOSE
7.17
HIGH
7.19
LOW
7.16
VOLUME
6.97M
TURNOVER
--
52 WEEK HIGH
7.22
52 WEEK LOW
3.060
MARKET CAP
2.66B
P/E (TTM)
-3.2150
1D
5D
1M
3M
1Y
5Y
1D
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
TipRanks · 1d ago
ATAI Life Sciences Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 4d ago
ATAI Life Sciences Price Target Cut to $7.50/Share From $25.00 by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Downgrades AtaiBeckley to Neutral, Lowers Price Target to $7.5
Benzinga · 4d ago
AtaiBeckley downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 4d ago
ATAIBECKLEY INC <ATAI.O>: H.C. WAINWRIGHT CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $7.5 FROM $25
Reuters · 4d ago
Cathie Wood’s ARK Invest adds another $57M to SpaceX, sells $39M stake in AMD
Seeking Alpha · 4d ago
Weekly Report: what happened at ATAI last week (0713-0717)?
Weekly Report · 4d ago
More
About ATAI
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.

Webull offers AtaiBeckley Inc stock information, including NASDAQ: ATAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATAI stock methods without spending real money on the virtual paper trading platform.